normative
Single-agent activity paradigm broken for checkpoint combos
A cardinal rule of drug development—ensure something has single-agent activity before combining it—is broken for immunotherapy, because some checkpoint molecules aren't even expressed until you administer another drug, so combination therapies must be tested directly and understood mechanistically rather than first proving each agent alone.
normativepending
Speaker
James P. AllisonEvidence Quote
“That paradigm is shot here because some of those molecules aren't even expressed until you give one of the other ones.”
Created: 6/13/2026, 12:24:01 AM
Your notes
Loading notes...